Posts in Knowledge Base

Nitrosamine Impurities: Managing a Risk That Has Not Gone Away

The regulatory deadlines for nitrosamine impurities have passed, but the obligation has not. What began in 2018 as an urgent response to contaminated sartans has[…]

ISO 27001 and Data Integrity: Information Security Risks in a GxP Environment

Information security has quietly become a GMP concern. As pharmaceutical operations move to cloud platforms, connected instruments and AI-assisted systems, the confidentiality and integrity of[…]

The EU Medical Technology Framework: A Compliance Roadmap for 2026 and Beyond

The European Union’s medical technology rulebook — the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) — is the most demanding device[…]

Biosimilars in Europe: Interchangeability and the New Tailored Clinical Approach

By 2026 the European biosimilar framework has matured from cautious, case-by-case review into one of the most confident regulatory systems in the world — and[…]

The In Vitro Diagnostic Regulation: Transition Deadlines and the Path to Compliance

The In Vitro Diagnostic Medical Devices Regulation (IVDR), Regulation (EU) 2017/746, has applied since 26 May 2022, replacing the long-standing In Vitro Diagnostic Directive (98/79/EC).[…]

Joint Clinical Assessment for Gene Therapies: In Scope from Day One

Unlike most medicines, gene therapies have been subject to the EU Joint Clinical Assessment (JCA) since it began on 12 January 2025. As advanced therapy[…]

Joint Clinical Assessment for Rare Disease Therapies: Preparing for 2028

The EU Joint Clinical Assessment (JCA) will extend to orphan medicines from January 2028, drawing rare disease therapies into a single, EU-wide clinical assessment. For[…]

Serialisation and the Falsified Medicines Directive: Keeping the Supply Chain Safe

Since February 2019, almost every prescription medicine pack in the EU has carried two safety features — a unique 2D barcode and an anti-tampering device[…]

The Qualified Person and Batch Release: The Last Line of Defence

No medicinal product can be placed on the EU market until a Qualified Person (QP) has certified the batch. It is one of the most[…]

Paediatric Investigation Plans: Planning for Children from the Start

For most new medicines in the EU, studying the product in children is not optional. Under the Paediatric Regulation, a paediatric investigation plan (PIP) must[…]